Author Archive

Nominations for the 2017 MedChemComm Emerging Investigator Lectureship

The 2017 MedChemComm Emerging Investigator Lectureship is now open for nominations.

Nominations will close 14 November 2016.

The recipient of the lectureship will receive a contribution of up to £1000 towards speaking at a conference in 2017.

Qualification
The lectureship is open to candidates who received their PhD in 2007 or later and who have made a significant contribution to medicinal chemistry in their early career, particularly if they have brought new ideas to drug discovery.

How you can nominate
If you would like to nominate someone please email us (medchemcomm-rsc@rsc.org) with the following details:

  • Their name
  • Their affiliation
  • At least one paragraph explaining their achievements and why you think they should be considered

Additional supporting information, for example their CV, is very helpful in making a decision but is not mandatory for making a nomination.

Self-nominations are accepted but must be supported by a letter of support from your Head of Departments or similar person at your institute.

Selection
All qualified nominations will be considered and a short-list of candidates with be selected based on the information provided at nomination. The MedChemComm Editorial Board will then vote to select the recipient and the winner will be announced in late 2016.

Previous lectureship winners include:

  • Dr Alessio Ciulli (University of Dundee, UK)
  • Professor Richard Payne (University of Sydney, Australia)
  • Professor Patrick Gunning (University of Toronto, Canada)
  • Professor Christian Heinis (École Polytechnique Fédérale de Lausanne, Switzerland).
Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Dr Alessio Ciulli wins 2016 Emerging Investigator Lectureship

Dr Alessio Ciulli winner of the 2016 MedChemComm Emerging Investigator LectureshipCongratulations to Dr Alessio Ciulli from University of Dundee, UK, the recipient of the 2016 MedChemComm Emerging Investigator Lectureship.

The annual MedChemComm Emerging Investigator Lectureship is given to a researcher who has made a significant contribution to medicinal chemistry research in the early part of their career.

The Editorial Board have selected Dr Alessio Ciulli as this year’s recipient for his work tackling important biology with elegant chemistry; developing novel chemical tools to aid our understanding of BET bromodomain proteins and providing pioneering examples of understanding protein-protein interactions as a basis for discovering novel therapeutics.

On being told he had won Dr Ciulli said,

I feel truly honoured to have been selected to receive the MedChemComm Emerging Investigator Lectureship this year, and privileged to join such a distinguished list of former winners. It is a recognition to the excellent work of many students and postdocs in my group who have made key contributions to our discoveries over the past few years. I am excited to be given the opportunity to present some of our latest results at a conference later in the year.”

Alessio will be presenting his lectureship at this year’s EFMC International Symposium on Medicinal Chemistry in Manchester. Register now.

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

2016 MedChemComm Emerging Investigator Lectureship – Nominations open

We are pleased to announce that nominations for the 2016 MedChemComm Emerging Investigator Lectureship are now open and we are looking for your suggestions.

Nominations will close 22nd January 2016.

The recipient will receive a contribution of up to £1000 towards speaking at a conference of their choice.

Qualification
The lectureship is open to candidates who received their PhD on or after December 31st 2005 and who have made a significant contribution to medicinal chemistry in their early career, particularly if they have brought new ideas to drug discovery.

How to nominate
If you would like to nominate someone please email us (medchemcomm-rsc@rsc.org) with the following:

  • Their name
  • Their affiliation
  • At least one paragraph explaining their achievements and why they should be considered

Additional supporting information, for example their CV, would be very much appreciated but is not mandatory for making a nomination.

Self-nominations are accepted but must be supported by a letter of support from your Head of Departments or similar person at your institute.

Selection
The decision to award the lectureship will be made by a panel of MedChemComm Editorial Board members.

Previous Lectureship winners include:

  • Professor Richard Payne (University of Sydney, Australia)
  • Professor Patrick Gunning (University of Toronto, Canada)
  • Professor Christian Heinis (École Polytechnique Fédérale de Lausanne, Switzerland).
Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Phenotypic Drug Discovery Web Themed Issue

MedChemComm is delighted to announce a high-profile themed issue on Phenotypic Drug Discovery, due for publication online in mid-2016. The issue is being Guest Edited by Dr Fabien Vincent (Pfizer), Dr Jonathan A. Lee (Eli Lilly) and Professor Michael Pollastri (Northeastern University).

Deadline for Submission: February 1, 2016

The level of quality of this issue will be high, and all manuscripts will subject to the journal’s normal standards and peer review process. Guidelines are available at rsc.li/1K0EgYx and rsc.li/1JAwCbA

If you are interested in taking part in this issue, please email MedChemComm: medchemcomm-rsc@rsc.org

Scope of the issue

Phenotypic approaches are highly complementary to the molecular target centric strategy that prevails in Pharma and moreover, may mitigate future clinical failure issues related to target validation and lack of efficacy. Five years into the Phenotypic Drug Discovery (PDD) Renaissance, this issue aims to shift the main focus in this area from assays and screens towards the medicinal chemistry programs engendered by these early efforts. Manuscripts covering the lessons learned and progress recorded on the road to clinical candidates in the areas highlighted below are actively sought:

  • Design of compound libraries for phenotypic screening (e.g. biologically annotated, diversity-based and natural products libraries)
  • Identification of novel targets for disease-relevant phenotypes
  • Identification of novel chemical matter or molecular mechanisms of action for known molecular targets
  • Identification of novel cellular roles for known targets
  • Challenges in PDD hit triage such as compound/series prioritization and validation
  • Challenges in driving an SAR  using complex assay systems (in vitro and in vivo systems)
  • Safety derisking and compound/project progression in the absence of a known target
  • Chemical biology approaches for mechanism and target deconvolution

New research in MedChemComm is published as Concise Articles. This article type encompasses both Communication and Full Paper styles with no strict page limit. There is also the opportunity to write a Review article for the issue, and if you would be interested in this please let us know.

MedChemComm is the Royal Society of Chemistry journal covering all areas of medicinal chemistry research, including research that interfaces with other areas of the chemical sciences, biology, materials science or physics

The journal is in partnership with the European Federation for Medicinal Chemistry (EFMC), and the co-Editors-in-Chief are Dr. Tony Wood (Pfizer) and Professor Greg Verdine (Harvard University). To view recent articles or to find out more about the journal please visit the website at www.rsc.org/medchemcomm

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Membrane Transporters: Solute Carriers themed issue launched

MedChemComm is delighted to announce a high-profile themed issue on Membrane Transporters, focussing on solute carriers (SLCs). The Guest Editors for this issue are Professor Matthias A. Hediger (University of Bern, Switzerland) and Dr David Hepworth (Pfizer, Cambridge, USA).

Deadline for Submission: December 14 2015

Please e-mail the Editorial Office if you are interested in contributing an article.

Manuscripts can be submitted using the Royal Society of Chemistry’s online article submission service. Please clearly state that the manuscript is submitted for the themed issue on Membrane Transporters: Solute Carriers.

The level of quality of this issue will be high, and all manuscripts will undergo the journal’s normal peer review process.

Scope

Metabolic homeostasis within cells requires strict control over the import and export of metabolites, nutrients and ions across membranes. Polar chemical species such as these have negligible ability to cross phospholipid membranes by simple diffusion and instead require highly regulated transport proteins to control their movement. The largest class of transport proteins is the solute carrier series (www.bioparadigms.org) and it is on this superfamily that this special issue of MedChemComm will focus.

These proteins are of great interest for basic academic research, but beyond that they are of central importance in a number of areas of applied science: as drug targets, as controllers of drug disposition and pharmacokinetics, and as the cause of drug toxicity.

Known SLC drug targets include:

  • The monoamine transporter family which contains the serotonin transporter (SLC6A4) target of the highly important SSRI drug class
  • SLC5A2 (SGLT2), an important new anti-diabetic target to block renal glucose reabsorption
  • Sodium chloride transporters (SLC12 family) – the targets of loop and thiazide diuretics

SLCs important in drug pharmacokinetics and disposition include

  • The OATP (SLCO) and OAT (SLC22) family  of anion transport
  • The OCT (SLC22) family of cation transport
  • The SLC47 multidrug and toxin extrusion family

SLCs important in drug toxicity include the thiamine transporter SLC19A2

All areas of research where the chemical sciences have impacted the study of the SLC superfamily will be considered for inclusion in this themed issue. Examples include, but are not limited to:

  • Medicinal chemistry and molecular probe design against these target families
  • Chemical biology approaches to allow for detailed study of these protein classes including physiological roles, disease mechanisms, etc.
  • Structural biology and biophysics of integral membrane proteins as relevant to ligand design and/or chemical biology
  • Molecular modelling that has enabled drug and probe design
  • The impact of transporters on drug disposition and pharmacokinetics – with a particular interest in structure activity relationships for such transport
  • The study of toxins and venoms which act through these target classes
  • Novel screening methodologies that allow the identification of new inhibitors, modulators and substrates of this protein class
  • The application of new cell biology techniques such as gene-editing, silencing and haploid genetic approaches that allow the study of chemical agents acting via these target families
  • Systems biology approaches to the study of chemical modulators and substrates of membrane transport proteins

The issue will consist of a series of research articles and reviews from prominent scientists who are committed to applying excellence in ion channels and membrane transporter research toward the treatment of human diseases, combining breakthroughs in both basic science and applied science, such as drug discovery.

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

2015 Emerging Investigator Lectureship

Earlier this year Professor Richard Payne from University of Sydney, Australia, was announced as the the recipient of the 2015 MedChemComm Emerging Investigator Lectureship.

We are pleased to let you know that Richard will be presenting his talk entilted:

New ligation technologies for the rapid assembly of modified proteins

at the upcoming Chemical Protein Synthesis (CPS) Meeting in St. Augustine, Florida on Friday the 19th of June.

The meeting starts on the 16th of June  2015 and online registration for the meeting closes the 10th of June – so there’s still time to register to see Richard’s talk!


UPDATE: Prof. Payne’s talk was very well received at the successful Chemical Protein Synthesis Meeting, where he (left) was presented his lectureship by Professor Stephen Kent (right).

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Wellcome Trust Frontier meeting: One Science – Life at the Interface

The Wellcome Trust is seeking 10 enthusiastic junior researchers currently undertaking interdisciplinary research, or who are wishing to pursue interdisciplinary collaborations, to attend their first Frontier meeting: One Science – Life at the Interface on 21-22 September 2015. Applications close on Friday 12th June 2015.

For full details, click on the image below

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Antimicrobial Resistance Article Collection

We are delighted to share with you a collection of research papers, review articles and books on the topic of antimicrobial resistance (AMR). Warnings about the threat of antibiotic resistance, and more broadly AMR, to human health, global food production and economic prosperity are receiving increased media interest. By 2050, it is estimated that without coordinated action, 10 million people could die from previously curable illnesses.

© iStock

“At the end of this month, the World Health Organisation (WHO) will present their draft global action plan on AMR at the 68th World Health Assembly in Geneva, it is timely to consider the importance of chemistry in tackling antimicrobial resistance,” comments Professor Sylvie Garneau-Tsodikova, Editorial Board member of MedChemComm “This collection showcases the essential contributions of chemical science to understanding antibiotic resistance, developing new treatments, diagnostics and mitigations strategies to tackle this global threat.”

“The chemical sciences play a pivotal role in a sustainable and prosperous future” says Dominic Tildesley, President of the Royal Society of Chemistry “whether it’s developing new antibiotics to combat infection, converting waste to energy, or developing efficient solar energy cells, chemists are designing and applying tomorrow’s technologies”.

All articles are freely available until 18th June. All books included here have their first chapter free to read.

Learn more about our work to support the chemical sciences community working on solutions in climate change, energy, food, health and water.

Having trouble acessing the articles? Remeber to login in to you free personal account to see all our free content.
Don’t have a free account? It’s quick and easy to create one now.


Why is it important to address AMR?

Thomas Fleming outlines the role of chemistry in tackling antibiotic resistance as part of our recent chemistry in health video competition Beating the Superbugs – avoiding an antibiotic apocalypse – a public panel discussion chaired by Michael Moseley, science journalist and TV presenter,  with scientists and policy makers to discuss the challenges and possible solutions to addressing AMR.

Design & synthesis of new antimicrobials


Reviews and Perspectives:

Plants as sources of new antimicrobials and resistance-modifying agents
Ana Cristina Abreu, Andrew J. McBain and Manuel Simões
Nat. Prod. Rep., DOI: 10.1039/C2NP20035J, Review Article

Antibiotics from myxobacteria
Till F. Schäberle, Friederike Lohr, Alexander Schmitz and Gabriele M. König
Nat. Prod. Rep., DOI: 10.1039/C4NP00011K, Review Article

Glycopeptide dendrimers as Pseudomonas aeruginosa biofilm inhibitors
Jean-Louis Reymond, Myriam Bergmann and Tamis Darbre
Chem. Soc. Rev., DOI: 10.1039/C3CS35504G, Review Article

Dithiolopyrrolones: biosynthesis, synthesis, and activity of a unique class of disulfide-containing antibiotics
Bo Li, Walter J. Wever, Christopher T. Walsh and Albert A. Bowers
Nat. Prod. Rep., DOI: 10.1039/C3NP70106A, Review Article

Ruthenium complexes as antimicrobial agents
Fangfei Li, J. Grant Collins and F. Richard Keene
Chem. Soc. Rev., DOI: 10.1039/C4CS00343H, Review Article

AApeptides as a new class of antimicrobial agents
Youhong Niu, Haifan Wu, Yaqiong Li, Yaogang Hu, Shruti Padhee, Qi Li, Chuanhai Cao and Jianfeng Cai
Org. Biomol. Chem., DOI: 10.1039/C3OB40444G, Perspective

Benzyl-substituted metallocarbene antibiotics and anticancer drugs
F. Hackenberg and M. Tacke
Dalton Trans., DOI: 10.1039/C4DT00624K, Perspective

Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa
Gaëtan L. A. Mislin and Isabelle J. Schalk
Metallomics, DOI: 10.1039/C3MT00359K, Minireview

Design and synthesis of membrane-targeting antibiotics: from peptides- to aminosugar-based antimicrobial cationic amphiphiles
Ido M. Herzog and Micha Fridman
Med. Chem. Commun., DOI: 10.1039/C4MD00012A, Review Article


Original research articles:

Synthesis of antimicrobial cyclodextrins bearing polyarylamino and polyalkylamino groups via click chemistry for bacterial membrane disruption
Hatsuo Yamamura, Yuuki Sugiyama, Kensuke Murata, Takanori Yokoi, Ryuji Kurata, Atsushi Miyagawa, Kenji Sakamoto, Keiko Komagoe, Tsuyoshi Inoue and Takashi Katsu
Chem. Commun., DOI: 10.1039/C3CC49543D, Communication

Phenazine antibiotic inspired discovery of potent bromophenazine antibacterial agents against Staphylococcus aureus and Staphylococcus epidermidis
Nicholas V. Borrero, Fang Bai, Cristian Perez, Benjamin Q. Duong, James R. Rocca, Shouguang Jin and Robert W. Huigens III
Org. Biomol. Chem., DOI: 10.1039/C3OB42416B, Communication

Polymers with tunable side-chain amphiphilicity as non-hemolytic antibacterial agents
Divakara S. S. M. Uppu, Padma Akkapeddi, Goutham B. Manjunath, Venkateswarlu Yarlagadda, Jiaul Hoque and Jayanta Haldar
Chem. Commun., DOI: 10.1039/C3CC43751E, Communication

Mechanism of Action of the Uridyl Peptide Antibiotics: An Unexpected Link to a Protein-Protein Interaction Site in Translocase MraY
Timothy Bugg, Maria Rodolis, Agnes Mihalyi, Christian Ducho, Kornelia Eitel, Bertolt Gust and Rebecca Jane Miriam Goss
Chem. Commun., DOI: 10.1039/C4CC06516F, Communication

Tailored lysozyme–ZnO nanoparticle conjugates as nanoantibiotics
Nirmalya Tripathy, Rafiq Ahmad, Seung Hyuck Bang, Jiho Min and Yoon-Bong Hahn
Chem. Commun., DOI: 10.1039/C4CC03712J, Communication

Inhibitors of bacterial tubulin target bacterial membranes in vivo
Marie H. Foss, Ye-Jin Eun, Charles I. Grove, Daniel A. Pauw, Nohemy A. Sorto, Jarred W. Rensvold, David J. Pagliarini, Jared T. Shaw and Douglas B. Weibel
Med. Chem. Commun., DOI: 10.1039/C2MD20127E, Concise Article

A structure activity-relationship study of the bacterial signal molecule HHQ reveals swarming motility inhibition in Bacillus atrophaeus
F. Jerry Reen, Rachel Shanahan, Rafael Cano, Fergal O’Gara and Gerard P. McGlacken
Org. Biomol. Chem., DOI: 10.1039/C5OB00315F, Paper

An organometallic structure-activity relationship study reveals the essential role of a Re(CO)3 moiety in the activity against gram-positive pathogens including MRSA
Malay Patra, Michaela Wenzel, Pascal Prochnow, Vanessa Pierroz, Gilles Gasser, Julia E. Bandow and Nils Metzler-Nolte
Chem. Sci., DOI: 10.1039/C4SC02709D, Edge Article

Non-classical β-carbonic anhydrase inhibitors-towards novel anti-mycobacterials
Natascha von Gnielinski, Lisa Nienaber, Lyndel Mason, Samantha Ellis, James A. Triccas, Rohan A. Davis and Andreas Hofmann
Med. Chem. Commun., DOI: 10.1039/C4MD00310A, Concise Article

Indole-based novel small molecules for the modulation of bacterial signalling pathways
Nripendra Nath Biswas, Samuel K. Kutty, Nicolas Barraud, George M. Iskander, Renate Griffith, Scott A. Rice, Mark Willcox, David StC. Black and Naresh Kumar
Org. Biomol. Chem., DOI: 10.1039/C4OB02096K, Paper

Synthesis, antiribosomal and antibacterial activity of 4′-O-glycopyranosyl paromomycin aminoglycoside antibiotics
Weiwei Chen, Takahiko Matsushita, Dimitri Shcherbakov, Heithem Boukari, Andrea Vasella, Erik C. Böttger and David Crich
Med. Chem. Commun., DOI: 10.1039/C4MD00119B, Concise Article

Antibacterial activity of adamantyl substituted cyclohexane diamine derivatives against methicillin resistant Staphylococcus aureus and Mycobacterium tuberculosis
Beena, Deepak Kumar, Widuranga Kumbukgolla, Sampath Jayaweera, MaiAnn Bailey, Torey Alling, Juliane Ollinger, Tanya Parish and Diwan S. Rawat
RSC Adv., DOI: 10.1039/C4RA00224E, Paper

N-Substituted 2-aminoimidazole inhibitors of MRSA biofilm formation accessed through direct 1,3-bis(tert-butoxycarbonyl)guanidine cyclization
Andrew A. Yeagley, Zhaoming Su, Kára D. McCullough, Roberta J. Worthington and Christian Melander
Org. Biomol. Chem., DOI: 10.1039/C2OB26469B, Paper

Development of ruthenium(II) complexes as topical antibiotics against methicillin resistant Staphylococcus aureus
P.-L. Lam, G.-L. Lu, K.-M. Hon, K.-W. Lee, C.-L. Ho, X. Wang, J. C.-O. Tang, K.-H. Lam, R. S.-M. Wong, S. H.-L. Kok, Z.-X. Bian, H. Li, K. K.-H. Lee, R. Gambari, C.-H. Chui and W.-Y. Wong
Dalton Trans., DOI: 10.1039/C3DT52879K, Paper

Synthesis and biological activity of novel bis-indole inhibitors of bacterial transcription initiation complex formation
Marcin Mielczarek, Ruth V. Devakaram, Cong Ma, Xiao Yang, Hakan Kandemir, Bambang Purwono, David StC. Black, Renate Griffith, Peter J. Lewis and Naresh Kumar
Org. Biomol. Chem., DOI: 10.1039/C4OB00460D, Paper

Potent growth inhibitory activity of (±)-platencin towards multi-drug-resistant and extensively drug-resistant Mycobacterium tuberculosis
Gamal A. I. Moustafa, Shoji Nojima, Yoshi Yamano, Akio Aono, Masayoshi Arai, Satoshi Mitarai, Tetsuaki Tanaka and Takehiko Yoshimitsu
Med. Chem. Commun., DOI: 10.1039/C3MD00016H, Concise Article

Thiazole-based aminopyrimidines and N-phenylpyrazolines as potent antimicrobial agents: synthesis and biological evaluation
Konstantinos Liaras, Athina Geronikaki, Jasmina Glamočlija, Ana Ćirić and Marina Soković
Med. Chem. Commun., DOI: 10.1039/C4MD00124A, Concise Article

Chlorido-containing ruthenium(II) and iridium(III) complexes as antimicrobial agents
Mallesh Pandrala, Fangfei Li, Marshall Feterl, Yanyan Mulyana, Jeffrey M. Warner, Lynne Wallace, F. Richard Keene and J. Grant Collins
Dalton Trans., DOI: 10.1039/C3DT32775B, Paper

Highly active antibacterial ferrocenoylated or ruthenocenoylated Arg-Trp peptides can be discovered by an L-to-D substitution scan
H. Bauke Albada, Pascal Prochnow, Sandra Bobersky, Julia E. Bandow and Nils Metzler-Nolte
Chem. Sci., DOI: 10.1039/C4SC01822B, Edge Article


Infection prevention and alternatives to address AMR


Books and Reviews:

Polymeric Materials with Antimicrobial Activity: From Synthesis to Applications
Alexandra Muñoz-Bonilla (Editor), María Cerrada (Editor), Marta Fernández-García (Editor)
ISBN (print): 978-1-84973-807-1, Copyright: 2013

Silver in Healthcare: Its Antimicrobial Efficacy and Safety in Use
Alan B. G. Lansdown (Author)
ISBN (print): 978-1-84973-006-8, Copyright: 2010

Photodynamic Inactivation of Microbial Pathogens: Medical and Environmental Applications
Michael R Hamblin (Editor), Giulio Jori (Editor)
ISBN (print): 978-1-84973-144-7, Copyright: 2011

Towards bacterial adhesion-based therapeutics and detection methods
Núria Parera Pera and Roland J. Pieters
Med. Chem. Commun., DOI: 10.1039/C3MD00346A, Review Article

Superhydrophobic surfaces for the reduction of bacterial adhesion
Xiaoxue Zhang, Ling Wang and Erkki Levänen
RSC Adv., DOI: 10.1039/C3RA40497H, Review Article

Nanosilver-based antibacterial drugs and devices: Mechanisms, methodological drawbacks, and guidelines
Loris Rizzello and Pier Paolo Pompa
Chem. Soc. Rev., DOI: 10.1039/C3CS60218D, Review Article


Original research articles:

Antimicrobial nanotechnology: its potential for the effective management of microbial drug resistance and implications for research needs in microbial nanotoxicology
Deborah M. Aruguete, Bojeong Kim, Michael F. Hochella, Yanjun Ma, Yingwen Cheng, Andy Hoegh, Jie Liu and Amy Pruden
Environ. Sci.: Processes Impacts, DOI: 10.1039/C2EM30692A, Critical Review

The promotion of antimicrobial activity on silicon substrates using a “click” immobilized short peptide
Lin Wang, Junjian Chen, Lin Shi, Zhifeng Shi, Li Ren and Yingjun Wang
Chem. Commun., DOI: 10.1039/C3CC47922F, Communication

An efficient strategy to achieve hydrophilic polymeric silver(I) materials with exceptional antibacterial activity
Sheng-Chun Chen, Zhi-Hui Zhang, Qun Chen, Li-Qun Wang, Juan Xu, Ming-Yang He, Miao Du, Xiao-Ping Yang and Richard A. Jones
Chem. Commun., DOI: 10.1039/C2CC36538C, Communication

Silver nanoparticle-embedded polymersome nanocarriers for the treatment of antibiotic-resistant infections
Benjamin M. Geilich, Anne L. van de Ven, Gloria L. Singleton, Liuda J. Sepúlveda, Srinivas Sridhar and Thomas J. Webster
Nanoscale, DOI: 10.1039/C4NR05823B, Paper

Antibacterial polymeric nanostructures for biomedical applications
Jing Chen, Fangyingkai Wang, Qiuming Liu and Jianzhong Du
Chem. Commun., DOI: 10.1039/C4CC03001J, Feature Article

Magnetic hybrid colloids decorated with Ag nanoparticles bite away bacteria and chemisorb viruses
Hye Hun Park, SungJun Park, GwangPyo Ko and Kyoungja Woo
J. Mater. Chem. B, DOI: 10.1039/C3TB20311E, Paper

Covalent attachment of multilayers (CAM): a platform for pH switchable antimicrobial and anticoagulant polymeric surfaces
Heather A. Pearson, Joseph M. Andrie and Marek W. Urban
Biomater. Sci., DOI: 10.1039/C3BM60238A, Paper

Multi-scale strategy to eradicate Pseudomonas aeruginosa on surfaces using solid lipid nanoparticles loaded with free fatty acids
Erik N. Taylor, Kim M. Kummer, Deepti Dyondi, Thomas J. Webster and Rinti Banerjee
Nanoscale, DOI: 10.1039/C3NR04270G, Paper

Bio-inspired resin acid-derived materials as anti-bacterial resistance agents with unexpected activities
Mitra S. Ganewatta, Yung Pin Chen, Jifu Wang, Jihua Zhou, Jerry Ebalunode, Mitzi Nagarkatti, Alan W. Decho and Chuanbing Tang
Chem. Sci., 2014, DOI: 10.1039/C4SC00034J, Edge Article

Antibacterial activity of Ionic Liquids based on ampicillin against resistant bacteria
Ricardo Ferraz, Vânia Teixeira, Débora Rodrigues, Rúben Fernandes, Cristina Prudêncio, João Paulo Noronha, Željko Petrovski and Luís C. Branco
RSC Adv., DOI: 10.1039/C3RA44286A, Paper

The surface charge of anti-bacterial coatings alters motility and biofilm architecture
Olena Rzhepishevska, Shoghik Hakobyan, Rohit Ruhal, Julien Gautrot, David Barbero and Madeleine Ramstedt
Biomater. Sci., DOI: 10.1039/C3BM00197K, Paper

Studies of the drug resistance response of sensitive and drug-resistant strains in a microfluidic system
Xiangdan Jiang, Yu Kang, Xingjie Pan, Jun Yu, Qi Ouyang and Chunxiong Luo
Integr. Biol., DOI: 10.1039/C3IB40164B, Paper

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Introducing MedChemComm Associate Editor Dr Matthew Fuchter

Dr Matthew Fuchter is a Senior Lecturer in Synthetic and Medicinal Chemistry within the Synthesis Group at the Department of Chemistry at Imperial College.

He completed PhD research under the supervision of Professor A. G. M. Barrett, FRS FMedSci and postdoctoral studies at the Commonwealth Scientific and Industrial Research Organisation, Australia, where he worked with Professor A. B. Holmes, FRS.

Prior to his position at Imperial College he was the RCUK Academic Fellow in Cancer Medicinal Chemistry at the School of Pharmacy (University of London). He returned to Imperial College in July 2008 as a Lecturer in Synthetic and Medicinal Chemistry and was promoted to Senior Lecturer in July 2012.

In 2014 he was awarded the RSC Harrison-Meldola Memorial Prize, as well as being admitted to the Royal Society of Chemistry as a Fellow.

At Imperial College he is heavily involved in research at the interface of chemistry and medicine. For example, he is a Managerial Board member of the anti-cancer drug discovery group, a Research Board member of the Institute of Chemical Biology and co-Director of the MRes in Drug Discovery.

Recent Publications:

Design, synthesis and initial characterisation of a radiolabelled [18F]pyrimidoindolone probe for detecting activated caspase-3/7
Org. Biomol. Chem., 2015, 13, 5418-5423, Paper

Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitors
Med. Chem. Commun., 2014, 5, 1821-1828, Concise Article
From themed collection Epigenetics

Perspectives on natural product epigenetic modulators in chemical biology and medicine
Nat. Prod. Rep., 2013, 30, 605-624, Review Article

Submit a manuscript for Matthew to handle

Visit Matthew’s Homepage


Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Introducing new Editorial Board member – Professor Andrea Cavalli

Andrea Cavalli is Professor of Medicinal Chemistry at the University of Bologna and Head of CompuNet at the Italian Istitute of Tecnology, Genova. Prof. Cavalli received his PhD in Pharmaceutical Sciences from the University of Bologna in 1999 and did postdoctoral work at SISSA (Trieste, Italy) and ETH (Zurich, Switzerland).

Prof. Cavalli’s research has combined computational chemistry with drug discovery, focusing on neurodegenerative diseases, cancer, and neglected tropical diseases. He has developed and applied computational tools and protocols to accelerate and enhance the discovery of novel lead and drug candidates. In particular, he has been a pioneer in the use of molecular dynamics simulations and related approaches to drug discovery. He is co-founder of a high-tech startup company (BiKi Technologies s.r.l.) focused on molecular dynamics and enhanced sampling in drug discovery. In an interdisciplinary effort, these approaches led to the identification and characterization of lead candidates within the framework of multitarget drug discovery and polypharmacology.

He is an author of more than 160 scientific articles published in high-ranked journals and inventor in several international patents. He has delivered numerous invited lectures and seminars at international congresses and prestigious institutions. In 2003, he was awarded the Farmindustria Prize for Pharmaceutical Research.

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)